Rapid impact of rotavirus vaccination in the United States: implications for Australia

Kristine K Macartney and Margaret A Burgess
Med J Aust 2009; 191 (3): . || doi: 10.5694/j.1326-5377.2009.tb02717.x
Published online: 3 August 2009

Australia is in a unique position to assess the impact of two different rotavirus vaccines

In 1973, Ruth Bishop and her colleagues in Melbourne were the first to identify rotavirus gastroenteritis in infants. Rotavirus has since been recognised as the most frequent cause of severe childhood gastroenteritis worldwide. In temperate climates, infection occurs predominantly in winter and spring.

  • Kristine K Macartney1
  • Margaret A Burgess1,2

  • 1 National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, NSW.
  • 2 Discipline of Paediatrics and Child Health, University of Sydney, Sydney, NSW.


Competing interests:

Margaret Burgess has received vaccine trial research support from, and given advice to, both GlaxoSmithKline and Merck/CSL. The National Centre for Immunisation Research and Surveillance is supported by the Australian Government Department of Health and Ageing, the New South Wales Department of Health, the University of Sydney and the Children’s Hospital at Westmead.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.